Table 3.
Distributional on NIS reviewed
| Distributional data on NIS | |||||
|---|---|---|---|---|---|
| Distribution of number of patients, number of healthcare professionals, number of patients per investigator and observational period (days) for each patienta | |||||
| Mean | Median | Maximum | Range | 25th–75th Percentile | |
| Number of patients | 2,445.6 | 600 | 30,000 | 29,980 | 300–1,500 |
| Number of healthcare professionals | 364.5 | 120 | 3,000 | 3,000 | 30–340 |
| Number of patients per healthcare professional | 15.4 | 5 | 500 | 499 | 3–8 |
| Observational period for each patient (in days) | 292.4 | 180 | 3,650 | 3,649 | 59–365 |
| Distribution of the 10 % of the NIS with the highest numbers of recruited patients | |||||
| Number of patients | |||||
| X-ray contrast agent | 30,000 | ||||
| X-ray contrast agent | 25,000 | ||||
| X-Ray contrast agent | 20,000 | ||||
| Antidepressant | 20,000 | ||||
| Eye drop (ocular hypertension and open-angle glaucoma) | 15,000 | ||||
| Antihypertensive agent | 15,000 | ||||
| Antihypertensive agent | 15,000 | ||||
| Eye drop (ocular hypertension and open-angle glaucoma) | 12,800 | ||||
| X-ray contrast agent | 12,000 | ||||
| Antibody (oncology therapy) | 12,000 | ||||
| Thrombocyte aggregation inhibitor | 10,000 | ||||
| Oral antidiabetic drug | 10,000 | ||||
| X-ray contrast agent | 10,000 | ||||
aIf defined precisely in the observational plan in advance